Process: Provide long-term appreciation through passive exposure to primarily large-cap US equities. Through O’Shaughnessy’s Canvas Custom Index platform, the investment process uses a risk-based ...

A new study published in Nature Communications identifies a molecular signaling pathway that contributes to the development of life-threatening aortic aneurysms and dissections in Marfan syndrome, a ...

Men diagnosed with metastatic hormone-sensitive prostate cancer who carry a specific tumor deficiency now have a targeted ...

Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth’s Board of Directors granted ...

OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today announced that it will host a virtual key opinion leader ...

You will be redirected to our submission process. Vascular dementia (VaD) is the second most common form of dementia globally, yet it remains significantly underserved by disease-modifying ...

FDA's rolling review process is intended to facilitate expedited review, enabling FDA to begin evaluating completed modules of the NDA before the full application is submitted FDA previously granted ...

FDA’s rolling review process is intended to facilitate expedited review, enabling FDA to begin evaluating completed modules ...

MISSISSAUGA, ON, June 23, 2026 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) is pleased to announce that it successfully ...

aBreast Cancer Now Research Centre, Institute of Cancer Research, London, UK bRalph Lauren Centre for Breast Cancer Research and Breast Unit, The Royal Marsden Hospital NHS Foundation Trust, London, ...

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that it has changed its corporate name to Faeth Therapeutics, Inc. (the “Company”). The Company’s common stock is expected to begin trading ...